Inno-206
Malignant Abdominal Neoplasm
Mayo ClinicEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Malignant Abdominal Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
OTL-38 Mayo Clinic | Phase 3 | B |
ERIBULIN MONOMETHANESULFONATE OHSU Knight Cancer Institute | Phase 1 | CC |
Bms-907351 M.D. Anderson Cancer Center | Phase 1 | CC |
Atezolizumab M.D. Anderson Cancer Center | Phase 1 | CC |
Sodium Thiosulfate Mayo Clinic | Early Phase 1 | C |
CIS-DIAMMINEDICHLOROPLATINUM II Mayo Clinic | Early Phase 1 | C |
Same molecule, other indications
Inno-206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →